UBS Upgrades Medtronic to Buy, Sees Turnaround Underway

AnalystEarnings
โดย Insider Monkey·US·Read original
Summary · why it matters

UBS upgraded Medtronic to Buy from Neutral, telling investors a turnaround is underway at the medical-device company. The upgrade follows Medtronic's report of its highest annual revenue growth in 10 years, with fiscal Q4 revenue reaching $9.8 billion, up 9.9% as reported and 6.6% organic, and full-year fiscal 2026 revenue of $36.4 billion, up 8.4% as reported and 5.8% organic. Cardiac Ablation Solutions revenue rose 78% globally, including 124% U.S. growth, and the Symplicity Spyral hypertension platform is now annualizing at $100 million. Management noted tariffs created a $74 million headwind in the quarter and expects a roughly $250 million impact in fiscal 2027, while guiding for organic revenue growth of 6.75% to 7.25% for the year.

Impact on stocks 1

Robotics & Physical AI▲ · 1 stocks
Medtronic PLC
MDT
▲ PositiveCapitalrelevance

UBS upgrade to Buy citing turnaround underway.

© 2026 MarketDXNews